What is the potency of meperidine (opioid analgesic) compared to morphine (opioid analgesic)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Meperidine Potency Compared to Morphine

Meperidine is approximately one-tenth as potent as morphine, meaning 60-80 mg of parenteral meperidine is roughly equivalent to 10 mg of parenteral morphine. 1

Equianalgesic Dosing

The FDA-approved drug label for meperidine clearly establishes the potency relationship:

  • 60-80 mg of parenteral meperidine = 10 mg of parenteral morphine 1
  • This translates to a potency ratio of approximately 6:1 to 8:1 (meperidine:morphine) 1
  • Alternatively stated, meperidine has roughly one-tenth the analgesic potency of morphine 2

Route-Specific Considerations

Oral administration of meperidine is significantly less effective than parenteral routes, though the exact oral-to-parenteral ratio remains unknown. 1 This poor oral bioavailability makes meperidine unsuitable for routine oral pain management. 3

For parenteral morphine conversions:

  • The onset of action with meperidine is slightly more rapid than morphine 1
  • Duration of action is slightly shorter (typically 3-4 hours) 3
  • Peak effects occur within 15-30 minutes with parenteral administration 3

Clinical Guidelines Context

NCCN guidelines describe tramadol as approximately one-tenth as potent as morphine 4, which places meperidine in a similar potency range. However, unlike tramadol, meperidine is a traditional mu-opioid receptor agonist without the dual mechanism of action. 4

Morphine remains the opioid of first choice for moderate to severe cancer pain 4, with meperidine generally considered a second-line agent due to its neurotoxic metabolite normeperidine. 3

Important Clinical Caveats

  • Meperidine should be considered a second-line agent when opioid analgesics are required 3
  • The active metabolite normeperidine has potent CNS excitatory toxicity, with half-life significantly prolonged in renal insufficiency 4
  • Meperidine is contraindicated with monoamine oxidase inhibitors (MAOIs) due to life-threatening drug interactions 4
  • Despite the established potency ratio, meperidine continues to be inappropriately prescribed, particularly for shorter courses of narcotic therapy 5

References

Research

[Usefulness of meperidine in anesthesiology].

Revista espanola de anestesiologia y reanimacion, 2000

Research

Meperidine: therapeutic use and toxicity.

The Journal of emergency medicine, 1995

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.